Pharma major Cipla is scheduled to report its fourth-quarter earnings on Tuesday. CNBC-TV18 poll estimated revenue to grow by 11 percent at Rs 5,097.2 crore in the March quarter of the financial year 2022 against Rs 4,606.5 crore in the same quarter last year despite falling demand for COVID-related drugs.

Cipla’s margin is likely to be supported by India business, but US price pressure could offset it. Analysts see margin range at 19-22 percent.

EBITDA is likely to grow by 30 percent to Rs 1,034 crore for the March quarter year-on-year, while margins may increase to 20.3 percent versus 17.3 percent on a year-on-year basis. Profit is likely to grow by 42 percent to Rs 586.9 crore for the March quarter versus Rs 413.4 crore for the same quarter a year ago.

The US sales are expected to be aided by Albuterol inhaler and gains in Sumatriptan. South Africa business likely to grow for co by 10-12 percent year-on-year, tender markets plus APIs could be subdued.

Management commentary on the US launch of Advair generic, Abraxane generic, domestic sales and launch of Revlimid generic would be key to watch.

Watch the video for more.

First Published:May 9, 2022 5:48 PM IST